secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001651308-25-000136
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025
--------------------------------------------------------------------------------

- Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.
- BCL2 inhibitor (BGB-11417) R&D spending surged to $94M from $39M YoY.
- CDAC (BGB-16673) R&D increased to $27M from $6M; CDK4 (BGB-43395) to $10M from $2M.
- Zanubrutinib R&D flat at $63M; Tislelizumab R&D up to $40M from $34M.
- Filing includes PRC GAAP vs U.S. GAAP reconciliation for share-based comp, income taxes, leasing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/0001651308-25-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000136/bgne-20250829.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer